|Last Price$64.99||Day Change (%)-2.53%|
|Open Price$65.65||Day Change ($)-1.69|
|Day Range64.26–65.70||52-Week Range54.80–71.90|
As of Fri 01/23/2015 05:11 PM EST | USD
The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.
MD Buyline Releases Q4.2014 “User Satisfaction Trending™” Data
Widening investment-grade credit spreads and rising interest rates lead to losses.
Each succeeding bailout entangles the global financial system even further.
There's steep price for no growth in these portfolios.
Week ending August 4
Industry dynamics are shifting in the wake of Zimmer's Biomet acquisition.
Increased investor inflows and portfolio reshuffling (driven in part by a fairly valued market), has added breadth to the high-conviction and new-money purchases we've seen so far from our top managers.
Obamacare will benefit some sectors more than others, but poor economy and pricing pressures are the biggest challenges most health-care firms must face.